Searching in Pharma & Drug Safety · Search everything
3,029 changes Pharma & Drug Safety
Washington University Patent for Toxoplasma Gondii Treatment Compounds
The USPTO granted Patent US12600727B2 to Washington University on April 14, 2026, covering compounds and methods for treating infections caused by Toxoplasma gondii and related parasites. The patent includes 18 claims and lists inventors L. David Sibley, Joshua Radke, Eamon Comer, Marshall Morningstar, and Bruno Melillo. This grant provides Washington University with exclusive intellectual property rights for the developed antiparasitic compounds and their pharmaceutical applications.
Interleukin-17 Inhibitors Patent - Novartis AG
The USPTO granted patent US12600728B2 to NOVARTIS AG covering novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds as Interleukin-17 (IL-17) inhibitors. The patent also protects processes for preparing these compounds, pharmaceutical compositions, and medicaments for treating diseases and disorders mediated by IL-17.
NURIX BTK Degrading Compounds, 36 Claims, Apr 14
The USPTO granted Patent US12600732B2 to NURIX THERAPEUTICS, INC. on April 14, 2026. The patent covers 36 claims for bifunctional compounds that degrade BTK via the ubiquitin proteolytic pathway, along with pharmaceutical compositions and methods of treatment for various diseases, conditions, or disorders.
ONO Pharmaceutical ABHD6 Antagonist Patent US12600730B2
USPTO granted Patent US12600730B2 to ONO Pharmaceutical Co., Ltd. on April 14, 2026, covering substituted cyclopenta[c]pyrrole compounds as ABHD6 antagonists for pharmaceutical use. The patent includes 18 claims for compounds useful in preventing or treating diseases associated with ABHD6 enzyme inhibition. The application was filed on April 8, 2024.
ELI LILLY AND COMPANY - KRAS Inhibitor Compounds for Cancer Treatment Patent Grant
The USPTO granted Patent US12600733B2 to Eli Lilly and Company on April 14, 2026, covering KRAS inhibitor compounds for treating cancer. The patent includes 30 claims for compounds of specified formula and their use in pharmaceutical compositions. Filing date was September 30, 2025.
Benzazepine derivative for vasopressin receptor disease treatment
Benzazepine derivative for vasopressin receptor disease treatment
Isoxazolo[5,4-H]quinazoline CDK Inhibitor Patent
USPTO granted patent US12600731B2 to Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. for isoxazolo[5,4-H]quinazoline compounds effective as cyclin-dependent kinase (CDK) inhibitors for treating cell proliferation disorders. The patent contains 23 claims and covers pharmaceutical compositions and methods of treating CDK-mediated diseases.
Halozyme US12600959B2 - Modified PH20 Hyaluronidase Polypeptides
USPTO granted Patent US12600959B2 to Halozyme, Inc. covering modified PH20 hyaluronidase polypeptides with enhanced stability and activity. The patent includes 15 claims spanning formulations, compositions, and uses thereof. Filing date was March 5, 2025, with application number 19071345.
Cell Reprogramming Methods, Integration-Free, iPSCs
Cell Reprogramming Methods, Integration-Free, iPSCs